Google
Trusted Resources: News & Events
Latest announcements and gatherings
From Early Hypothesis to Clinical Data About Reducing Vaso-Occlusive Episodes with Arginine Therapy
At the 40th American Society of Hematology (ASH) Annual Meeting and Exposition investigators discussed an early hypothesis about Arginine (Arg) therapy as treatment for vaso-occlusive episdes (VOEs) in patients with sickle cell disease (SCD).
Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy’s benefit, and her original premise. Her team’s phase 3 trial evaluating Arg is currently underway.
The primary outcome for the latest data was total parenteral opioid use in milligrams per kilo of IV morphine. Despite the unexpected interruptions of severe pain experienced by this patient population, treatments for acute pain related to sickle cell disease are lacking.
+myBinderRelated Content
-
Discovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
-
Executive functioning and health-related quality of life in pediatric sickle cell diseaseResearch consistently indicates that chi...
-
Sickle cell pain in the emergency departmentSickle cell disease is characterized by ...
-
Lifespan Comprehensive Sickle Cell CenterThe Lifespan Comprehensive Sickle Cell C...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Annual Sickle Cell Road Race/WalkThe Sickle Cell Foundation of Georgia, I...
-
East Carolina University Comprehensive Sickle Cell CenterEast Carolina University Comprehensive S...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.